The International Initiative on Thrombosis and Cancer (ITAC) is the international section of the Groupe Francophone Thrombose et Cancer (GFTC).

GFTC is a French not-for-profit clinical research organization that promotes optimal treatment and prophylaxis of cancer-associated venous thromboembolism (CAT) at the point of care worldwide. Through ITAC, the organization develops international evidence-based clinical practice guidelines on the treatment and prophylaxis of CAT, and promotes their dissemination through educational initiatives and the production of a free interactive guideline mobile application. ITAC develops international clinical practice guidelines through an appointed international guideline steering committee, and a structured review process by an international advisory board of more than 100 members. The GFTC also conducts clinical trials and contributes to venous thromboembolism (VTE) & cancer patient databases.

The GFTC first initiated the development of international clinical practice guidelines for the treatment and prophylaxis of VTE in patients with cancer in 2011. The group published its first international clinical practice guidelines in the Journal of Thrombosis and Hemostasis using GRADE methodology under the auspices of the Institut du Cancer (INCa) and the International Society on Thrombosis and Cancer (ISTH) in 2013. These international clinical practice guidelines were updated under the direction of ITAC in 2016 and in 2019 and published in Lancet Oncology with endorsement from the ISTH.

The international ITAC clinical practice guidelines are available through an internationally accessible free mobile application which provides recommendations on the use of anticoagulants for the prevention and treatment of CAT. The app is currently available in English, French, Spanish, Portuguese, and Russian.